IP Verse

Aav -Vectors For Use In Gene Therapy Of Choroideremia - EP2678435

The patent EP2678435 was granted to Isis Innovation on Feb 7, 2024. The application was originally filed on Feb 21, 2012 under application number EP12706308A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2678435

ISIS INNOVATION
Application Number
EP12706308A
Filing Date
Feb 21, 2012
Status
Patent Maintained As Amended
Jan 5, 2024
Publication Date
Feb 7, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STRAWMANFeb 15, 2019MEWBURN ELLISADMISSIBLE

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTWO0168888
INTERNATIONAL-SEARCH-REPORTWO2004084951
INTERNATIONAL-SEARCH-REPORTWO2009097129
INTERNATIONAL-SEARCH-REPORTWO2011088081
OPPOSITIONWO0168888
OPPOSITIONWO02082904
OPPOSITIONWO2004084951
OPPOSITIONWO2011088081
OPPOSITIONWO2012114090

Non-Patent Literature (NPL) Citations (50) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- AAO_Gene Therapy Restores Partial Vision - YouTube
OPPOSITION- AAO_ Gene Therapy Restores Partial Vision - YouTube Video
OPPOSITION- Archived webpage Choroideremia Research Foundation
OPPOSITION- archived webpage - Miguel Seabra_TEDx Lisboa
OPPOSITION- Archived webpage University of Pennsylvania
OPPOSITION- Clinical trial NCT02407678
OPPOSITION- Conference programme
OPPOSITION- Curcio 1987
OPPOSITION- Declaration of Professor James Bainbridge (CV annexed)
OPPOSITION- Declaration of Prof MacLaren and CV
OPPOSITION- Gene Therapy for treatment of Severe Eye Disease -www.pointsdevue.net - Essilor YouTube Video
OPPOSITION- Gene Therapy for treatment of Severe Eye Disease - YouTube
OPPOSITION- Institute Gulbenkian De Ciencia Annual Report
OPPOSITION- Interview of Dr Jean Bennett
OPPOSITION- Interview of Dr Jean Bennett and Dr Arnold Maguire
OPPOSITION- Kolstad 2010
OPPOSITION- Lecture by Dr Jean Bennett
OPPOSITION- Lecture by Dr Miquel Seabra 15 May 2010
OPPOSITION- MACLAREN, "An analysis of retinal gene therapy clinical trials: successful translation will depend on successful translation", Europe PMC Funders Group Author Manuscript, (20090000), pages 1 - 11, XP055575365
OPPOSITION- Marangoni 2014
OPPOSITION- Mookherjee 2015
OPPOSITION- NIH VideoCast - Seeing is Believing A Gene Therapy Success
OPPOSITION- Ochakovski 2017
OPPOSITION- OSTAD-SAFFARI et al., "Persistent Expression of Non-Viral SIMAR Vectors in the RPE for Choroideremia Gene Therapy (3122/A346)", ARVO conference poster abstract, (20100000), XP055575608
OPPOSITION- Panda-Jones 1996
OPPOSITION- Retnet, (20100500), URL: https://web.archive.org/web/20100527040624/http://www.sph.uth.tmc.edu/Retnet/disease.htm
OPPOSITION- Retnet (http://www.sph.uth.tmc.edu/RetneVdisease.htm)archived webpage May 2010 showing CHM entry
OPPOSITION- Seeing is Believing A Gene Therapy Success - YouTube
OPPOSITION- Seeing is Believing A Gene Therapy Success - YouTube Video
OPPOSITION- TEDxLisboa-Miguel Seabra - Terapia genica: substituir genesque nao funcionam
OPPOSITION- TEDxLisboa-Miguel Seabra - Terapia genica: substituir genesque nao funcionam - Video
OPPOSITION- Webpage showing date of Miguel Seabra lecture
OPPOSITION- TOLMACHOVA et al., "Functional expression of Rab escort protein 1 following AAV2-mediated gene delivery in the retina of choroideremia mice and human cells ex vivo", J Mol Med, (20130000), vol. 91, no. 7, pages 825 - 837, XP055110987
OPPOSITION- Surace et al., "Versatility of AAV vectors for retinal gene transfer", Surace and Auricchio, Vision Research, (20080000), vol. 48, no. 3, pages 353 - 359, XP022452229
OPPOSITION- ANAND et al., "Gene therapy for choroideremia: in vitro rescue mediated by recombinant adenovirus", Vision Research, (20030000), vol. 43, no. 8, pages 919 - 926, XP055495142
OPPOSITION- BESSANT et al., "Molecular genetics and prospects for therapy of the inherited retinal dystrophies", Genetics of disease, (20010601), vol. 11, no. 3, pages 307 - 316, XP055575419
OPPOSITION- BUCH et al., "AAV-mediated gene therapy for retinal disorders: from mouse to man", Gene Therapy, (20080600), pages 849 - 857, XP055110973
OPPOSITION- SIMONELLI et al., "Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration", Am Soc Gene & Cell Ther, (20100000), vol. 18, pages 643 - 650, XP055575599
OPPOSITION- BAINBRIDGE et al., "Gene therapy progress and prospects: the eye", Gene Therapy, (20060000), vol. 13, no. 16, pages 1191 - 1197, XP055070610
OPPOSITION- BAINBRIDGE et al., "Effect of gene therapy on visual function in Leber's congenital amaurosis", N E J Med, (20080000), vol. 358, no. 21, pages 2231 - 2239, XP002718542
OPPOSITION- MAGUIRE et al., "Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis", New England Journal of Medicine, (20080000), pages 2240 - 2248, XP055027817
OPPOSITION- DINCULESCU et al., "Adeno-associated virus-vectored gene therapy for retinal disease", Human Gene Therapy, (20050000), vol. 16, no. 6, pages 649 - 663, XP003031412
OPPOSITION- HAUSWIRTH et al., "Treatment of Leber Congenital AmaurosisDue to RPE65 Mutations by Ocular Subretinal Injection of Adena- Associated Virus Gene Vector: Short-Term Results of a Phase I Trial", Human Gene Therapy, (20081000), XP055575361
OPPOSITION- TOLMACHOVA et al., "P33 Gene Therapy Studies in the Mouse Model of Choroideremia", HUMAN GENE THERAPY BSGT 2009 POSTER PRESENTATIONS, (20090000), page 407, XP055575392
OPPOSITION- TAN et al., "Gene therapy for retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIPL1: effective rescue of mouse models of partial and complete Aipl1 deficiency using AAV2/2 and AAV2/8 vectors", Human Molecular Genetics, (20090000), vol. 18, no. 12, pages 2099 - 2114, XP055489691
OPPOSITION- TOLMACHOVA et al., "Retinal Pigment Epithelium Defects Accelerate Photoreceptor Degeneration in Cell Type-Specific Knockout Mouse Models of Choroideremia", Invest. Ophthal. & Vis Sci, (20100000), vol. 51, no. 10, pages 4913 - 4920, XP055027781
OPPOSITION- TOLMACHOVA et al., "Independent degeneration of photoreceptors and retinal pigment epithelium in conditional knockout mouse models of choroideremia", The Journal of Clinical Investigations, (20060200), vol. 118, pages 386 - 394, XP055575435
OPPOSITION- Gelga Kolb, "How the Retina Works", American Scientist, (20030100), vol. 91, pages 28 - 35, XP055575406
OPPOSITION- Campochiaro P A, "Gene therapy for retinal and choroidal diseases", Campochiaro Expert Opin Biol Ther, (20010000), vol. 2, no. 5, pages 537 - 544, XP009025756
OPPOSITION- STIEGER et al., "Preclinical Studies on Specific Gene Therapy for Recessive Retinal Degenerative Diseases", Current Gene Therapy, (20100000), vol. 10, pages 389 - 403, XP055575604

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents